Guardant Health (GH) Expected to Announce Earnings on Thursday

Guardant Health (NASDAQ:GH - Get Free Report) is expected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $192.50 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Guardant Health Price Performance

Guardant Health stock traded up $1.14 during mid-day trading on Friday, hitting $48.12. 2,129,865 shares of the company were exchanged, compared to its average volume of 2,321,910. The business's 50 day simple moving average is $39.02 and its two-hundred day simple moving average is $31.05. The company has a market capitalization of $5.95 billion, a P/E ratio of -11.35 and a beta of 1.32. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares of the company's stock, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 2,652 shares of company stock worth $93,192. 5.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on GH shares. Guggenheim reissued a "buy" rating on shares of Guardant Health in a research report on Wednesday, January 22nd. The Goldman Sachs Group raised their price target on Guardant Health from $36.00 to $49.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th. Barclays initiated coverage on Guardant Health in a report on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Sixteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.